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Abstract

Acute myocardial infarction (MI) remains a leading cause of morbidity and mortality
worldwide. Accompanying MI is myocardial ischemia/reperfusion (MI/R) injury, which
results in cardiac contractile dysfunction and additional myocardial cell death. MIIR
injury is initiated in pati by mitochondrial-derived reactive oxygen species due to
mitochondrial membrane potential collapse and uncoupling of the electron transport
chain, which may be due to mitochondrial fission in MIIR. Mitochondrial fission is in
turn associated with shotiening/fragmentation of mitochondria, decreased ATP
production, and is thought to promote cardiac contractile dysfunction and post-reperfused
cardiomyocyte loss, leading to increased infarct size. Therefore, inhibiting mitochondrial
fission may be an effective new strategy to salvage injured cardiomyocytes during MI/R.
Dynamin related protein 1 (Drp1) is a cytosolic GTPase that promotes mitochondrial
fission via interaction with various outer mitochondrial membrane proteins. Mdivi-1
(MW= 353.22 g/mol), a mitochondrial fission inhibitor that acts by selectively inhibiting
Drp1 GTPase activity, was used to test this strategy. Isolated perfused rat heatis subjected
to 30 min ischemia and 90 min reperfusion exhibited significantly higher infarct size 46%
± 3% (n=9) compared to sham heatis (minimal infarct size), which did not undergo 1/R.

Administration ofMdivi-1 (25 J.!M) for 5 min following ischemia significantly reduced
infarct size to 24% ± 2% (n=7), as compared to control 1/R heatis (p< 0.01). Moreover,
control 1/R hearts showed significantly compromised peak rates of rise in the first
derivative ofleft ventricular developed pressure (+dP/dtmax) of 656.98 ± 90.02 mmHg/s
and left ventricular developed pressure (LVDP) of 35.36 ± 5.06 mmHg compared to
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sham hearts (+dP/dtmax of 1998.69 ± 195.87 mmHg/s and LVDP of76.69 ± 9.12 mmHg)
at the end ofthe experimental protocol (both p<0.01). By contrast, Mdivi-1 treatment
significantly improved +dP/dtmax to 1101.83 ± 132.24 mmHg/s, LVDP to 49.85 ± 2.69
mmHg, compared to untreated control 1/R hearts at the end of reperfusion (both p<0.05).
These results suggest that inhibition of mitochondrial fission may be an effective strategy
to mitigate heali injury in MI patients.
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1
Introduction
Summary

Coronary heart disease (CHD) provoking myocardial infarction (MI) is the
leading cause of death and disability worldwide (Hausenloy and Yellon, 2013). Current
treatments for MI include primary percutaneous coronary intervention (PPCI),
thrombolytic therapy, aspirin, nitrates, beta-adrenergic and calcium channel blockers, and
angiotensin conve1ting enzyme inhibitors (Mayo Clinic Staff, March 06, 2014). However,
a large pmtion of cardiomyocyte death seen in MI patients is caused by myocardial
ischemialreperfusion (MI/R) injuries, a problem not resolved in any of these
contemporary treatments. For this reason, innovative strategies to protect the heart are
necessary to improve clinical outcomes in patients who have suffered MI.
MIIR injury is a pathological condition involving the generation of reactive
oxygen species (ROS) leading to cardiomyocyte death following a decrease in blood
flow, a condition called ischemia, and the restoration of oxygen rich blood, an event
called reperfusion. Similar diseases such as diabetes, atherosclerosis, and obesity serve as
high risk factors for CHD. Prolonged myocardial ischemia leads to cardiac tissue
damage, myocardial infarction, and abnmmal heart rhythms (Mayo Clinic Staff, March
06, 2014). Timely reperfusion to the heart is currently the most effective therapeutic
intervention to reduce acute MIIR injury and potentially save a patient's life. Reperfusion
is most commonly achieved clinically via PPCI, otherwise known as angioplasty
(Hausenloy and Yell on, 2013 ). Threading a catheter through the inguinal femoral or
radial mtery and the related blood vessels until the blockage site in the specific coronary
artery is found is how cardiologists perfmm PPCI. A balloon is then inflated to widen
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the narrowed or obstructed mteries, thus allowing blood to again flow through the artery
to perfuse the myocytes in the ischemic area to reduce the infarct size (Cohen, 2014).
However, it is valuable to understand that although reperfusion is effective in limiting
final infarct size, the act of reperfusion will also contribute to infarct size (Figure 1). In
other words, aside from bringing oxygenated blood to the ischemic tissue, the initial
subsequent effects ofreperfusion paradoxically augment injury, rather than alleviate the
unfavorable environment. Therefore, prevention ofreperfusion injury can further
attenuate infarct size. Many mechanisms are involved in reperfusion injury. Recently,
mitochondrial fission, or shortening/fragmentation of mitochondria, has been shown to be
associated with MI/R and is thought to promote cardiac contractile dysfunction and postreperfused cardiomyocyte loss, leading to increased infarct size (Disatnik et al., 2013;
Sharp et al., 2014).
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Figure 1. Illustration of the individual contributions of acute MI injury and myocardial
reperfusion injury to final MI size in MI patients up to 24 hours following PPCI.
(Hausenloy and Yellon 2013).
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Overview of Ischemia
The mechanism of ischemia involves an oxygen-depleted period, which halts
oxidative phosphorylation along the mitochondrial membrane, leading to mitochondrial
membrane depolarization, ATP depletion, and inhibition of myocardial contractile
function (Figure 2). Additionally, cellular metabolism switches to anaerobic glycolysis
due to oxygen depletion during ischemia, resulting in the accumulation of lactic acid,
which lowers intracellular pH to less than 7.0. At this pH level, a protein pore on the
mitochondrial inner membrane called the mitochondrial petmeability transition pore
(MPTP) is assembled, but remains closed. The further accumulation of protons due to
lactate accumulation activates the sodium-hydrogen (Na+-H+) ion exchanger in order to
mitigate the unwanted hydrogen ions by extruding them for sodium ion entry. At the
same time, ATP depletion slows the sodium-potassium (N a+-K+) pump, which relies on
ATP for its function, further increasing the intracellular Na+ overload (Hausenloy and
Yellon, 2013). The responding mechanism to increased intracellular Na+ is the twosodium-calcium (2Na+-Ca2+) ion exchanger. This exchanger is driven by concentration
gradients on either side of the cellular membrane and thus leads to excessive Ca2+ influx.
A rise in mitochondrial Ca2+ may also occur under such conditions, but is only modest,
since the mitochondria are largely de-energized in the absence of oxygen (Allen et al.,
1993; Griffiths and Halestrap, 1995; Miyata et al., 1992). Without oxygen's role as the
final electron acceptor in oxidative phosphorylation, ATP generation wanes. Without
ATP, the myosin head is unable to reset itself for myofibril contracture. Therefore,
myofibril contracture is inhibited during this period. The acidic conditions developed
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during ischemia due to lactic acid generation, prevent the opening of the MPTP and
further lead to cardiomyocyte contracture inhibition.
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Figure 2. Mechanism oflschemia in cardiomyocytes. (Adapted from Hausenloy and
Yellon 2013).

Overview of Reperfusion
Reperfusion on the other hand is the intervention used to return freshly
oxygenated blood to the ischemic tissue, but consequently reactivates the electron
transpmi chain in the mitochondria, generating ROS (Figure 3). It does this by catalyzing
the one-electron reduction of molecular oxygen (02), forming superoxide anion (02 •- ).
Superoxide is convetied to hydrogen peroxide (H20 2) through the action of superoxide
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dismutases (SODs) both within the mitochondria and in the cytosol (Hamanaka and
Chandel, 2010).
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Figure 3. Complexes 1 and 3 in the electron transport chain are responsible in releasing
0 2- during I/R (Adapted from Szeto and Schiller, 2011).

ROS also mediate MI/R injury by inducing the opening of the MPTP, act as neutrophil
chemoattractants, and mediate dysfunction of the sarcoplasmic reticulum. This leads to
increased intracellular Ca2+ from the sarcoplasmic reticulum, cell membrane damage due
to lipid peroxidation, enzyme denaturation, and direct oxidative damage to DNA
(Hausenloy and Yellon, 2013). Washout oflactic acid upon reperfusion and reactivation
of the Na+-H+ ion exchanger to extrude excess hydrogen ions restores the pH to normal
levels. Excess Ca2+ is driven into the mitochondria upon the restoration of the
mitochondrial membrane potential, which can also induce MPTP opening. In response to
the release ofROS, cytokines, and activated complement, neutrophils (i.e. 3-4 hours postreperfusion) accumulate in the infarcted myocardial tissue (Tsao et al., 1990). The
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mitochondria, though dysfunctional, are now able to produce ATP again because 0 2 is
available. ATP availability in combination with increased Ca2+ emergence from the
sarcoplasmic reticulum results in myofibril hypercontracture (Hausenloy and Yell on,
2013). Hypercontracture occurs due to this excess Ca2+ binding to troponin in the
cardiomyocytes causing confmmational changes in troponin that allow more tropomyosin
to move away from the myosin-binding sites on actin. Thus, more cross-bridges are
fmmed between actin and myosin, triggering extra contraction. This high intracellular
Ca2+ and myofibril hypercontracture is responsible for diastolic dysfunction (increase in
diastolic pressure). Diastolic dysfunction is detrimental because the elevated pressure
prevents adequate relaxation of the ventricles to refill with blood to pump to the rest of
the body. Moreover, the myocardial tissue cannot receive the crucial blood supply that it
requires because it is during diastole that the coronary blood flow is perfused to these
cardiomyocytes.
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Figure 4. Mechanism of reperfusion in cardiomyocytes. (Adapted from Hausenloy and
Yellon 2013).
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MI/R injury involves a series of events in which oxidative stress is crucial to
initiating these events. Unfmiunately, administration of antioxidants has not been
effective in clinical trials. Therefore, targeting ROS sources may lead to a novel
treatment strategy. It is essential to cultivate understanding of the mechanisms in which
MIIR injury occurs and develop innovative methods to attenuate MI/R injury. Doing so
will help to preserve post-reperfused cardiac function, limit infarct size, reduce mortality,
and improve the quality of life for MI patients. Cunently, mitochondrial derived ROS
may be an impmiant source of oxidative stress during MI/R (Kloner et al., 2012; Sharp et
al., 2014).

Mitochondrial Significance
Mitochondria, which are extremely plentiful in cardiomyocytes (i.e. up to 40%)
due to the high demand for ATP, are central to both cellular metabolism and apoptosis.
ROS produced by the mitochondria during stress can be hmmful to their own lipids,
proteins, and DNA and lead to mitochondrial dysfunction (Hamanaka and Chandel,
2010). However, low levels ofROS can be beneficial to the cardiovascular system. These
low levels of ROS play a role in vascular smooth muscle cell proliferation and
differentiation, along with angiogenesis. Increased ROS lead to loss of mitochondrial
membrane potential, which signals mitochondrial fission and mitophagy (Kim et al.,
2007; Lemasters et al., 1998; Scherz-Shouval and Elazar, 2011). Therefore, identifying
the inhibitory mechanisms of mitochondrial fission is essential in understanding
cardiomyocyte viability during MI/R.
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Mitochondrial Dynamics
Mitochondria are highly dynamic organelles that frequently change their shape in
response to a cell's metabolic demands or pathological conditions. Various
mitochondrial-shaping proteins control mitochondrial fission and fusion events. Among
them are human fission protein 1 (Fis 1), mitochondrial fission factor (Mft), and
mitochondrial elongation factor 1 (MIEF1). These three integral proteins reside on the
outer mitochondrial membrane and serve as receptors. Mitochondrial fission occurs when
there is increased fragmentation (i.e. shortening), whereas mitochondrial fusion (i.e.
elongation) occurs due to increased tethering between two adjacent mitochondria (Zhao
et al., 2013). These mitochondrial dynamics are regulated via a GTPase called dynamin
related protein 1 (Drp 1), which resides in the cytosol. During an ischemic event such
MI/R, a calcium-activated phosphatase, calcineurin, becomes activated. This calcineurin
enzyme will dephosphorylate Drp 1 at a specific serine site called S63 7. Upon
dephosphorylation, Drp 1 will translocate to one of the three outer mitochondrial
membrane protein receptors: Fis1, Mff, or MIEFl. When Drp1 interacts with Fis1 or
Mff, fission is promoted.
Conversely, when Drp1 interacts with MIEF1, Drp1-driven mitochondrial fission
is inhibited; fusion is promoted. This may also be in patt due to MIEF 1
oligodimerization between two adjacent mitochondria. Another possible interaction
occurs between Fis 1 complexing with MIEF1. Fis 1 will block the inhibitory action
nmmally exhibited by MIEF1, thus preventing Drp1 from binding to MIEFl. Thereby,
this interaction will relieve the inhibitory effect on Drp1 (Zhao et al., 2013).
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In addition to MIEFI, mitochondrial fusion is coordinated by three other
mitochondrial membrane proteins, which include Mitofusin 1 (Mfnl) and Mitofusion 2
(Mfn2) acting on the outer mitochondrial membrane, and optic atrophy 1 (OPAl), acting
on the inner membrane (Zhao et al., 2013). Both Mfnl and Mfn2 are attached on the
outer mitochondrial membrane by two transmembrane pmiions and can form homo- and
heterodimers through interactions that serve to tether the outer membranes between
adjacent mitochondria together (Chen et al., 2003; Koshiba et al., 2004). OPAl is
similarly able to tether opposing inner membranes together, leading to mitochondrial
inner membrane fusion via GTP hydrolysis (Koshiba et al., 2004). As stated earlier,
MIEFI also contributes to mitochondrial fusion, independent ofMfnl, Mfn2 and OPAl.
Mitochondrial fusion allows mitochondria to maintain membrane potential by fusing
depolarized mitochondria to intact ones, while fission allows the segregation of
umecoverable mitochondria so they can be eliminated by mitophagy, which is a
specialized fmm of autophagy (Ikeda et al., 20 15) (Figures 5 and 6).
Mfn112
OPA1

MIEF1

Fusion
_.

Figure 5. Proteins involved in mitochondrial fusion. (Adapted from Zhao et. al. 2013).
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Figure 6. Illustration summarizing mitochondrial fission and fusion events. (Adapted

from Dorn et al. 2014) (Dorn and Kitsis, 2015).

Recent studies suggest mitochondrial dynamics may patticipate in MI/R injury
(Disatnik et al., 2013; Ong et al., 2010; Qi et al., 2013; Sharp et al., 2014). Previous
studies have shown during MI/R that Drp1 is a regulator of mitochondrial morphology
and Drp 1 activation primarily binds to Fis 1, and less to Mff and MIEF -1 , leading to
mitochondrial fission (Disatnik et al., 2013; Sharp et al., 2014). Fmthermore,
mitochondrial fission decreased 0 2 consumption, lowered ATP production, and increased
ROS generation (Disatnik et al., 2013). By contrast, acute inhibition of excessive
mitochondrial fission using PliO, a peptide that inhibits Drpl and Fisl interaction,
attenuated mitochondrial dysfunction and decreased infarct in isolated perfused rat heatts.
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However, this study did not measure post-reperfused cardiac function (Disatnik et al. ,
2013; Qi et al., 2013). Another mitochondrial fission inhibitor, Mdivi-1, that inhibits the
Drpl GTPase activity, was shown to improve post-reperfused cardiac function in isolated
perfused rat heatis, suggesting attenuation of mitochondrial fission (Sharp et al., 2014).
However, this study did not measure infarct size at the end of the experimental procedure.
Collectively, these two studies have yielded encouraging results,
suggesting that attenuation of mitochondrial fission may be an important mechanism to
limit cardiac dysfunction and cell death in MI/R. However, it is clear that additional
studies need to be performed with Mdivi-1 and PliO to assess infarct size and cardiac
function in MI/R respectively.

Regulation of mitochondrial dynamics via a mutually exclusive Interplay of MIEF1 with Drp1 and Fls1
Key components of the
mammalian fission machinery

Drp1

Orp1

Calcineurin

Mfl

Fisl

MIEF1

I

r

Figure 7. Regulation of mitochondrial dynamics via Drpl. (Adapted from Zhao et al.
2013).
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Role of Mitochondria in Apoptosis
Mitochondria are fundamental organelles in many apoptotic responses.
Drp 1translocation leading to mitochondrial fission plays an essential role in mediating
mitophagy in mouse embryonic fibroblast cells and Bnip3- (a pro-apoptotic BH3-only
protein) -induced autophagy in adult cardiomyocytes. Overexpression ofDrp1 has also
been shown to induce mitochondrial fission, increase apoptosis, and decrease
mitochondrial membrane potential in cardiomyocytes (Ikeda et al., 2015; Ong et al.,
2010). However, whether this translates to an overall increase in myocardial infarct size
when exposed to global I (30 min)/R (90 min) has yet to be determined. Agitation of the
outer mitochondrial membrane often leads to the release of apoptotic factors, namely
cytochrome c. Fis 1 has previously been shown to cause the release of cytochrome c and
ultimately apoptosis following the fragmentation of the mitochondrial network (James et
al., 2003).
Cytochrome c is mostly localized in the mitochondrial intermembrane space
under nmmal physiological conditions (Neupett, 1997). Stimulation of Fis 1 via
interaction with Drp 1 may lead to the release of cytochrome c from mitochondria to the
cytosol where it activates a caspase family of proteases, triggering apoptosis (Kraemer et
al., 1998). Normally, cytochrome c binds to cardiolipin, which is an impmtant component
of the inner mitochondrial membrane, comprising 20% of the total lipid composition.
Mitochondrial ROS production is stimulated during the early phase of apoptosis, and
cardiolipin becomes oxidized by the cardiolipin-cytochrome c complex, which has a
peroxidase function (Orrenius and Zhivotovsky, 2005). The elevation in Ca2+ levels and
assembly of the MPTP due to MIIR injury precedes cytochrome c release from the
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mitochondria. Cytochrome c will then interact with the inositol trisphosphate receptor
(IP3R) on the endoplasmic or sarcoplasmic reticulum (ER or SR respectively) depending
on location, causing the ER or SR to release Ca2+. The overall increase in Ca2+ elicits
fmiher cytochrome c release through the MPTP. Cytochrome c also patiicipates as a
component of the apoptotic protease-activating factor (Apaf-1). This cytochrome c-Apaf1 association results in the formation of the apoptosome protein complex, which can
recruit and activate pro-caspase 9 (Li et al., 1997). Cytochrome c in turn also activates
caspase 9, which is a cysteine protease that can then go on to activate caspase 3 and
caspase 7, which are responsible for cellular apoptosis (Boehning et al., 2003) (Figure 9).

ER

/SR

Cytosol
IP3 Receptor

Cytochrome c

Complex I

Complex Ill

Complex II

Complex IV

ATP Synthase

Figure 8. Cytochrome c apoptotic pathway. (Adapted from Sigma-Aldrich, Cytochrome
c schematic).
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Mdivi-1

The implications of these mitochondrial dynamics were studied using Mdivi-1
(Sigma-Aldrich Chemicals, StLouis, MO., MW= 353.22 g/mol), a small molecular
mitochondrial division inhibitor, which functions by selectively inhibiting Drp 1. The
chemical formula ofthis drug is 3-(2,4-Dichloro-5-methoxyphenyl)-2,3-dihydro-2thioxo-4( 1H)-quinazolinone, 3 -(2,4-Dichloro-5-methoxyphenyl )-2-sulfanyl-4(3 H)quinazolinone (Sigma-Aldrich Staff, 2015). Mdivi-1 is a cell-petmeable molecular
inhibitor, which directly binds to Drp1, inhibiting its GTPase activity and thus its
function on Fis1, Mff, or MIEF1 (Ong et al., 2010) (Figures 7 and 9).
Previous studies have shown that treatment of cardiomyocytes with Mdivi-1 every
24 hours for 1 week prevented mitochondrial fission and inhibited foreshortening of
mitochondria (Ikeda et al., 2015). Additionally Mdivi-1 has been shown to be
cardioprotective in ex vivo LangendorffMI/R rat hearts (Sharp et al., 2014). However,
this study group did not cany out reperfusion past 20 min, nor did they observe infarct
size following experiments. In our study, we extended reperfusion time to 90 min
following 30 min ischemia. Moreover, we evaluated infarct size at the end of our
experiments. In principle, Mdivi-1 represents a class of therapeutics for stroke,
myocardial infarction, and neurodegenerative diseases (Sigma-Aldrich Staff, 2015).

O
*CI
OC;~I
OCH3

N

SH

Figure 9. Mdivi-1 molecular structure. (Adapted from Sigma-Aldrich).
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Hypothesis
We hypothesize that Mdivi-1, when given during reperfusion in isolated perfused
rat hemis following thitiy minutes of global ischemia, will provide cardioprotective
effects. This study will evaluate these cardioprotective effects by measuring cardiac
function and infarct size of each myocardium throughout the experiments. We will cany
out reperfusion for a total of ninety minutes post-ischemia. We hypothesize that the use
ofMdivi-1 will significantly reduce infarct size and preserve post-reperfused cardiac
function when compared to untreated control I/R hemis. The outcomes of this research
will benefit heati attack and organ transplantation patients in attenuating IIR-induced
organ damage.
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Methods
Langendorf{ Heart Preparation
The Institutional Animal Care and Use Committee of the Philadelphia College of
Osteopathic Medicine approved all animal protocols perfmmed in this study. This study
utilized Sprague-Dawley rats whose weights ranged from 275-325 g. They were
anesthetized through a peritoneal injection of pentobarbital sodium (60 mg/kg) and
heparin (1000 U) to prevent coagulation. Upon opening the peritoneum, 8 mL of blood
was drawn from the abdominal aorta using a 20-gauge needle fastened to a 10 mL
syringe, containing 1 mL of citrate phosphate buffer. The heatt was isolated from the rat
and perfused with a modified Krebs ' buffer through the ascending amta. The aorta was
cannulated to the perfusion needle using surgical suture and lowered into a 160 mL
water-jacketed reservoir containing 37°C Krebs' buffer to provide the preload for the
heatt. A constant pressure of 80 rnmHg, aerated with 95% 0 2 and 5% C02 , a temperature
of37°C, and a pH between 7.35- 7.45 was maintained using the Langendorffhemt
preparation (Blakeman et al., 2012). The Krebs' buffer is composed of the following: 25
mM NaHC0 3 -, 17 mM dextrose, 5.9 mM KCl, 120 mM NaCl, 0.5 mM EDTA, 2.5 mM
CaCb, and 1.2 mM MgCb. The blood sample was placed in a centrifuge for 10 min at
10,000 g and 4°C to isolate plasma. A pressure transducer was insetted into the left
ventricle from the base of the heatt. See Figure 10 for the perfused hemt preparation.
Baseline readings are carried out to 15 min to achieve accuracy as well as to ensure a
stable cardiac function. Following stable baseline recordings, Krebs' buffer flow was
blocked to induce ischemia. After 30 min, the flow was resumed along with either 5 mL
of plasma for the control I/R hemts, or 5 mL of plasma plus 25 f!M ofMdivi-1 (Sigma-
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Aldrich Chemicals, StLouis, MO., MW= 353.22 g/mol) delivered using an infusion
pump (Harvard Apparatus, Holliston, MA) via a three-way stopcock proximal to the
hemt. Mdivi-1 is purchased from Sigma-Aldrich in the form of a white powder stored at 20°C, which is then solubilized with the organosulfur compound dimethyl sulfoxide
(DMSO) for direct infusion to the Langendorf[ ex vivo heart (final DMSO concentration
0.1%). The plasma/buffer, or plasma/buffer with drug was delivered at an infusion rate of
1 mL/min. An illustrated version of this protocol is diagramed in Figure 11. An infusion
recording was taken initially at 2 min and a reperfusion recording every 5 min thereafter
for a 90 min reperfusion period (Blakeman et al., 2012). LVDP, which is the left
ventricular end-systolic pressure (L VESP) minus left ventricular end-diastolic pressure
(LVEDP), and the maximal rate ofLVDP (+dP/dtmax) and minimum rate ofLVDP (dP/dtmin) were taken every 5 min during baseline and reperfusion. Coronary flow was
measured using a flow meter (T106, Transonic Systems, Inc., Ithaca, NY) and a pressure
transducer was (SPR-524, Millar Instruments, Inc., Houston, TX), inserted through the
mitral valve and into the left ventricle to record cardiac function data. Data were recorded
using a Powerlab Station acquisition system (AD Instruments, Grand Junction, CO). After
90 min ofreperfusion, the hemt was removed from the perfusion needle, frozen at -20°C,
and cross-sectioned from apex to base into 2 mm pieces. The sections were subjected to
1% triphenyltetrazolium chloride (TTC) staining for 15 min at 37°C. This helped to
distinguish viable tissue, which stained red, from dead tissue, which did not stain. The
infarct size is calculated as a percentage of dead tissue to total tissue weight.
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Figure 10. Langendorffheart preparation .
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Figure 11. Protocol of isolated perfused rat heart for I/R injury.
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Treatment Groups

1) Sham Hearts: Sham or (placebo) hearts were not subjected to ischemia, unlike the
control I/R hea1ts. This group is used to see whether the isolated heart with Krebs'
buffer perfusion can maintain cardiac function throughout the experimental
protocol (i.e. 135 min). After 15 min of initial baseline recordings, Krebs' buffer
was allowed to continually flow for an additional30 min. The Krebs' buffer is
then followed by 5 mL infusion of Sprague-Dawley rat plasma for a 90 min
recording period. The sham hemts will have nearly normal cardiac function
throughout the experimental period with little to no visible infarcted tissue. This
group of hearts was used to demonstrate that indeed normal cardiac function
could be maintained outside the body throughout the experimental period.
2) MIIR Hemts (untreated, I/R control): Following stable baseline readings,
ischemia was induced in the hea1ts for 30 min by stopping the flow of Krebs'
buffer. After 30 min of ischemia, reperfusion was started by restoring the flow of
Krebs' buffer, which would continue for 90 min with the infusion of 5 mL of
plasma immediately at the beginning of reperfusion. Control or untreated MI/R
hemts were used to determine the cardiac dysfunction and infarct size caused by I
(30 min)/R (90 min) compared to sham hemts and to drug-treated MI/R hemts.
This was performed to determine if the drug had a true effect on either cardiac
function or infarct size. Control hearts subjected to I (30 min)/R (90 min) showed
a compromised cardiac function and a larger infarct size compared to sham hemts. ·
3) MIIR Hearts treated with Mdivi-1: These hemt preparations underwent 30 min of
ischemia. Reperfusion began by restoring the flow of Krebs' buffer for 90 min
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with the combined infusion of 5 mL of plasma and 25

~M

ofMdivi-1 during the

first 5 min ofreperfusion (Sharp et al., 2014). Mdivi-1 treated MI/R hearts were
used to detetmine the drug's effects on post-reperfused cardiac function and
infarct size when compared to untreated control MI/R hearts.
Table 1. MIIR Treatment groups

Groups

Sample size (n)

Sham

5

Control I/R

9

Mdivi-1 (25J-LM)

7

Isolation of Plasma
Approximately 8 mL of blood was removed from the rat's abdominal amia. 1 mL
of citrate phosphate buffer (Sigma Chemical Co., St. Louis MO) was then added before
the plasma was isolated. The blood was than centrifuged at 10,000 Gat 4°C for 10 min.
The plasma was decanted (5 mL) and used in all treatment groups. The plasma was
prepared depending on the treatment group and then infused into the isolated heati via the
three-way stopcock via a syringe infusion pump (Harvard Apparatus, Holliston, MA) at 1
mL/min for the first 5 min of reperfusion.
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TTC Staining and Measurement of Infarct Size
After 90 min of reperfusion, the hearts were placed in -20°C for 30 min and were
cross-sectioned from apex to base in 2 mm thick sections. The hearts were stained with
TTC to detect the infarct size. The 2 mm sections were then placed in a water incubator at
37°C for 15 min. Photographs were taken of each side of each stained section. The viable
tissue stained red due to the TTC being reduced to 1,3,5-triphenylfmmazan (TPF) in
response to the dehydrogenase activity (Umemoto, 1985). The dead tissue remained
unstained due to the loss of the dehydrogenase enzyme from the damaged cell. The
unstained tissue is excised, weighed, and then recorded using Microsoft Excel software.
The infarct size is calculated by the weight ratio of unstained tissue to the total weight of
each 2 mm section.

Statistical Analysis
All statistical data in the text and figures are presented as means± S.E.M, and
analyzed by ANOVA using post hoc analysis with the Student-Newman-Keuls test for
the cardiac function and infarct size. p<0.05 was considered statistically significant.
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Results
Cardiac Function
Multiple parameters of cardiac function were measured and quantified over the
course of the experiments. Initial data measurements represent the last recording taken
following a stable baseline (~ 15 min) and final measurements represent completion of the
90 min time point of reperfusion. The cardiac function parameters quantified for each
experiment include LVDP, +dP/dtmax, LVESP, -dP/dtmitl> LVEDP, heart rate, and
coronary flow. The experiments conducted include sham, control I/R, or I/R + Mdivi-1
(25 )lM) treated heatis.
Left Ventricular Developed Pressure (L VDP)
Figure 12 diagrams the initial vs. final LVDP values for each experimental group.
There was no significant difference observed in initial LVDP recordings among all
groups. Sham heatis maintained a LVDP of76.69 ± 9.12 rnrnHg throughout the whole
time course of the experiment. By contrast, untreated control I/R hearts show a LVDP of
35.36 ± 5.06 rnrnHg at 90 min ofreperfusion, which was significantly lower compared to
sham heatts. Notably, administration ofMdivi-1 (25 )lM) significa,ntly improved LVDP
to 49.85 ± 2.69 rnrnHg at 90 min ofreperfusion compared to untreated control I/R heatts.
The control 1/R and Mdivi-1 treated hea1ts resulted in a LVDP of38 ± 6% and 59± 4%
of initial baseline recordings, respectively, compared to baseline. Figure 13 illustrates the
time course of LVDP among sham, control I/R, and I/R + Mdivi-1 (25 )lM) treated
hemts. Untreated control I/R hemts showed significantly lower LVDP throughout the
whole reperfusion period. Fmthetmore, Mdivi-1 significantly improved LVDP at the 5,
10, 15, 20, 25, 30, 35, 40, 80, 85 and 90 min points of reperfusion compared to untreated
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control I/R hemis (p<0.05). The final LVDP for the Mdivi-1 drug treated group was
significantly increased compared to the untreated control I/R group. These data indicate
that Mdivi-1 (25 11M) significantly restored post-reperfused cardiac contractile function
(LVDP) compared to untreated control I/R hemis. Refer to Figures 12 and 13 .
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Final LVDP
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Figure 12. Initial vs. final LVDP for sham, control I/R, and I/R + Mdivi-1 hearts.
(*p<0.05) Mdivi-1 vs. IIR.
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Figure 13. Time course ofLVDP for Sham, I/R, and IIR + Mdivi-1 hemis. Mdivi-1 (25
11M) given at reperfusion for the duration of 5 min significantly restored early and late
post-reperfused cardiac contractile function (LVDP) compared to untreated I/R hemis
(*p<0.05, * *p<O.O 1).
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Maximal Rate of Rise in Left Ventricular Pressure (+dP/dtmax)

Figure 14 diagrams the initial vs. final +dP/dtmax values for each experimental
group. There was no significant difference observed in initial +dP/dtmax recordings among
all groups. Sham hemis maintained a +dP/dtmax of 1998.69 ± 195.87 mmHg/s throughout
the whole time course of the experiment. By contrast, untreated control I/R heatis showed
a +dP/dtmax of 656.98 ± 90.02 mmHg/s at 90 min of reperfusion, which was significantly
lower, compared to sham hearts. Markedly, administration of Mdivi-1 (25 f.LM) improved
+dP/dtmax to 1101.83 ± 137.24 mmHg/s at 90 min ofreperfusion compared to untreated
control I/R hearts. The control I/R and I/R + Mdivi-1 hemis resulted in a +dP/dtmax of28
± 4%, and 50± 7% respectively, compared to baseline. Figure 15 illustrates the time
course of +dP/dtmax among sham, control IIR, and I/R + Mdivi-1 (25 f.LM) treated hemis.
Untreated control I/R hearts showed significantly lower +dp/dtmax values throughout the
whole reperfusion period. Fmihe1more, Mdivi-1 significantly improved +dp/dtmax at 5,
10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 75, 80, 85, and 90 min compared to the
control I/R hearts (p<0.05). The final +dp/dtmax for the Mdivi-1 drug treated group was
significantly increased compared to the untreated control IIR group. These data indicate
that Mdivi-1 given at reperfusion for the duration of 5 min significantly restored postreperfused cardiac contractile function (+dP/dtmax) compared to untreated control I/R
hemis. Lastly, sham experiments recovered to near baseline recordings (>90%). See
Figures 14, 15 and Table 2.
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Figure 14. Initial vs. final +dP/dtmax for sham, control 1/R, and 1/R + Mdivi-1 (25 j..tM).
(*p<0.05) Mdivi-1 vs. 1/R.
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Figure 15. Time course of +dP/dtmax for Sham, 1/R, and 1/R + Mdivi-1 hearts. Mdivi-1
(25 f!M) given at reperfusion for the duration of 5 min. significantly restored postreperfused cardiac contractile function (+dP/dtmax) compared to untreated I/R hearts
(*p<0.05, **p<0.01).

26

Table 2. Initial vs. Final L VDP and +dP/dtmax comparison
(*p<0.05) compared to control I/R

Initial L VDP
(mmHg)

Initial
Final
+dP/dtmax
+dP/dtmax
(mmHg/s)
(mmHg/s)
2280.13 ± 92.13 1998.69 ± 195.87

Sham
(n=S)

91.91 ± 4.95

Final
LVDP
(mmHg)
76.69 ± 9.12

Control I/R
(n=9)

95.35 ± 3.81

35.36 ± 5.06

2382.65 ± 73.38 657.0 ± 90.02

I/R + Mdivi-1
(25 J!M)
(n=7)

85.105 ± 3.3

49.848 ± 2.69 *

2270.27 ± 88.15

1101.83 ± 132.24 *

Left Ventricular End Systolic Pressure (L VESP)
Another measure of cardiac contractility includes the left ventricular end systolic
pressure (L VESP). Figure 16 diagrams the initial vs. final L VESP values. Sham hemis
maintained a LVESP of 83.66 ± 10.26 mmHg throughout the whole time course of the
experiment. Conversely, untreated control I/R hearts demonstrated an increased LVESP
of90.85 ± 4.98 mmHg at 90 min ofreperfusion, which was not significantly altered,
compared to sham hemis. Administration of Mdivi-1 (25 )lM) did not affect LVESP at 90
min of reperfusion (1 01.34 ± 7. 7 mmHg) compared to untreated control 1/R hearts. These
data indicate there was no significant difference observed in L VESP across each
experimental group. Refer to Figure16.
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Figure 16. Initial vs. final LVESP for sham, control I/R, and IIR + Mdivi-1 (25

~-tM).

Maximum Rate of Fall in Left Ventricular Pressure (-dP/dtmin)
Figure 17 diagrams the maximal rate of fall in the first derivative of left
ventricular pressure -dP/dtmin· This parameter is used to quantify cardiac relaxation, or
diastolic function. There was no significant difference observed in initial recordings fordP/dtmin and LVEDP among all groups. Sham hearts maintained a -dP/dtmin of -1238.56 ±
152.12 mmHg/s throughout the whole time course of the experiment. Conversely,
untreated control 1/R hearts show a -dP/dtmin of -624.93 ± 67.76 mmHg/s at 90 min of
reperfusion, which was significantly lower, compared to sham hearts. Administration of
Mdivi-1 (25

~-tM)

did not improve -dP/dtmin at 90 min ofreperfusion (-700.491 ± 50.14

mmHg/s) compared to untreated control I/R hearts. See Figure 17.
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Figure 17. Initial vs. fmal -dp/dtmin for sham, control I/R, and I/R + Mdivi-1 (25 )lM).

Left Ventricular End Diastolic Pressure (LVEDP)
Another measure of diastolic function, or cardiac relaxation includes the left
ventricular end diastolic pressure (LVEDP). Figure 18 diagrams the initial vs. final
LVEDP values. Sham hearts maintained a L VEDP of 6.97 ± 1.49 mmHg throughout the
whole time course of the experiment. Conversely, untreated control I/R heatis show a
LVEDP of54.169 ± 5.84 mmHg at 90 min ofreperfusion, which was significantly
higher, compared to sham hemis. Administration ofMdivi-1 (25 )lM) did not affect
LVEDP at 90 min ofreperfusion (51.492 ± 7.72 mmHg) compm·ed to untreated control
I/R hearts. These data indicate there was no significant difference observed in LVEDP for
drug treated and untreated control I/R hemi groups. Refer to Figure 18.
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Figure 18. Initial vs. final LVEDP for sham, control 1/R, and 1/R + Mdivi-1 (25 )lM).

Heart Rate & Coronary Flow Rate
The integrated cardiac parameters include heati rate, coronary flow rate, and
infarct size. Figures 19 and 20 diagram the initial vs. final heart rates and coronary flow
rates for each experimental group, respectively. Sham hemis maintained a hemi rate of
267.33 ± 11.72 BPM throughout the whole time course of the experiment. Conversely,
untreated control 1/R hemis show a hemi rate of289.54 ± 33.74 BPM at 90 min of
reperfusion, which was not significantly different, compared to sham hemis.
Administration ofMdivi-1 (25 )lM) did not affect heart rate at 90 min ofreperfusion
(240.298 ± 11.27 BPM) compared to untreated control 1/R hemis. These data indicate
there was no significant difference observed in hemi rates for all experimental 1/R heart
groups. Refer to Figure 19.

30

;---,

•

Initial HR

•

FinaiHR

250

~

0...

~200

.....ClJ
~ 150
(I)

ClJ

(I)

I

100
50
0

Sham (n=5)

1/R (n=9)

1/R + Mdivi-1 25uM (n= 7)

Figure 19. Initial vs. final heati rate for sham, control 1/R, and I/R + Mdivi-1 (25 11M).

Figure 20 diagrams initial vs. final coronary flow rates. Sham hemis maintained a
flow rate of 15.29 ± 2.34 mL/min throughout the whole time course of the experiment.
However, untreated control I/R hemts displayed a flow rate of7.93 ± 0.59 mL/min at 90
min of reperfusion, which was significantly lower, compared to sham hearts.
Administration ofMdivi-1 (25 11M) did not increase flow rate at 90 min ofreperfusion
(7.16 ± 0.57 mL/min) compared to untreated control 1/R hemts. These data indicate there
was no significant difference observed in coronary flow rates for drug treated and
untreated control 1/R heart groups. Refer to Figure 20.
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Figure 20. Initial vs. final coronary flow rate for sham, control I/R, and I/R + Mdivi-1
(25 ).LM).

Cardiac Infarct Size
Following each experiment, TTC staining was used to asce11ain the infarct size
after 30 min of ischemia (global ischemia; the whole heart is at risk) and 90 min of
reperfusion. Figure 21 depicts three photographs taken from representative left
ventriclular cross-sections from each treatment group. The sham heart only showed
minimal infarct size. However, the untreated control IIR hearts demonstrated larger
infarct size, mainly located in the mid-myocardial tissue. By contrast, Mdivi-1 treated I/R
healis showed smaller infarct size, when compared to untreated control I/R healis. Figure
22 summarizes the weight ratio of infarcted to at risk tissue for sham, control IIR, and I/R

+ Mdivi-1. Mdivi-1 hemts (25 ).LM) significantly reduced infarct size to 24% ± 2% (n=7)
compared to untreated control I/R hearts (n=9) that had an infarct size of 46% ± 3% (**
p<O.Ol).
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Sham

1/R

1/R + Mdivi-1

Figure 21. Representative left ventricular heart cross sections of sham, 1/R, and IIR +
Mdivi-1, subjected to TTC staining. Viable tissue stained red, while the infarcted tissue
remained unstained (white).
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• Sham (n=5) • 1/R (n=9) • 1/R + Mdivi-1 25 uM (n=7)

Figure 22. Weight ratios of infarcted/at risk left ventricular tissue in sham, 1/R, and 1/R +
Mdivi-1 as determined by TTC staining. ** p<0.01 Mdivi-1 vs. IIR.
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Discussion
Summary of Major Findings
The major findings from this study are listed as follows. Control IIR hearts
displayed compromised cardiac function and increased infarct size following I (30 min)/
R (90 min) of reperfusion. Mdivi-1 (25

~M)

treated I (30 min)/ R (90 min) hearts

significantly improved post-reperfused cardiac function and reduced infarct size
compared to control I/R hearts.
Cardiac Dysfunction and Infarct under 1/R
Under IIR conditions, we observed cardiac contractile dysfunction. Control I/R
hearts showed compromized contractility such as reduced LVDP, +dP/dtmax, and
increased LVESP. Normally, oxygen present in the the vasculature provides the
mitochondrial electron transport chain with the final electron acceptor it requires to
synthesize ATP. Additionally, Ca2+ stored in the SR becomes available to bind to
troponin sites on tropomyosin, leading to conformational changes that expose the myosin
binding sites on the actin filament. This increase in Ca2+ plus ATP availablity provides
the power necessary for the myocardium to contract. Likewise, the reuptake of Ca2+ into
the SR allows myofibril relaxation.
However, during an ischemic event such as in MIIR, oxygen becomes
unavailable. Decreased 0 2 renders a decrease in A TP, inhibition of myofibril contracture,
and a change to anerobic respiration. Anerobic respiration increases hydrogen ions,
which stimulates the Na+-H+ ion exchanger, increasing intracellular Na+. The 2Na+-Ca2+
ion exchanger attemps to mitigate Na+ ions by extruding them for Ca2+ ions, which
ultimately leads to increased intracellular Ca2+ concentrations, even during diastole. This
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cascade of events aids in assembly of the the MPTP and dismpts the mitchondrial
innetmembrane potential. Morever, increased Ca2+ activates the Drpl GTPase, which
augments mitochondrial fission, oxidative stress, and ultimately autophagy (Hausenloy
and Yellon, 2013; Sharp et al., 2014). These ischemic events account for signifcant drops
in all cardiac function parameters (LVDP, +dP/dtmax, LVESP, LVEDP, -dP/dtmin, and
heart rate) during 30 min of ischemia in our experiment.
The restoration of blood during reperfusion, though necessary to salvage what
undamaged tissue remains, causes additional myocardial cell injury. By washout oflactic
acid (generated during ischemia), and reintroduction of molecular 02, the mitochondrial
electron transpmt chain reactivates, generating ROS and disrupting the SR. Ca2+ release
from the SR in combination with newly available ATP, lead to myofibril hypercontrature
and opening of the MPTP on the mitochondrial inner membrane. The MPTP further
uncouples the electron transpmt chain, enhancing ROS generation and releases
cytochrome c. Furthermore, ROS and cytochrome c contribute to mitochondrial
autophagy and thus influence MIIR injury (Hausenloy and Yellon, 2013).
Hypercontracture prevents the myocardium from properly relaxing, and therefore
influences the increases in both LVESP & LVEDP, and decreases in coronary flow rate,
as these smTounding myocytes are tightly constricted around the vasculature. Together,
increased ROS coupled with hypercontracture also clarify the decreased LVDP,
+dP/dtmax, -dP/dtmiih and increased infarct size when compared to sham hearts.
Cardioprotective effects of Mdivi-1
By using Mdivi-1 we targeted the GTPase Drp1, which nmmally leads to
mitochondrial fission upon MIIR. The calcium overload induced by 1/R, subsequently
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activates calcineurin, which desphosphylates the S637 site on Drp1, leading to Drp1
translocation to the mitochondrial outer membrane proteins. After Drp 1 binding to these
proteins (e.g. Fis1 and Mff) the Drp1 GTPase induces mitochondrial fragmentation (i.e.
fission). Mdivi-1 however inhibits the Drp1 GTPase, thus attenuating mitochondrial
fission. Normally, mitochondrial fission is involved with cell cycle progression to
accommodate energy demands. However, during I/R excessive mitochondrial fission
leads to decreased A TP and cardiac function and increased oxidative stress, cell death
and ultimately infarct size. Therefore, attenuating the aforementioned processes will
ultimately salvage cardiac tissue and function. Maintaining mitochondrial number and
size provides an additional function whereby mitochondria may act to buffer calcium
overload (Disatnik et al., 2013; Ong et al., 2010; Qi et al., 2013; Sharp et al., 2014).
Figure 23 depicts a flow diagram of this process.
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Figure 23. Overview ofDrpl activation pathway. (Adapted from Sharp et al. 2014).
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The Effects ofMdivi-1 (2SJ!M) on Cardiac Function and Infarct Size
For each experiment conducted, the same parameters were consistently measured,
LVDP, +dp/dtmax, -dp/dtmin, heart rate, coronary flow, LVESP, LVEDP and infarct size.
The Mdivi-1 treated group showed a significant increase in post-reperfused LVDP and
+dp/dtmax compared to the untreated control I/R group. Moreover, the notewmthy results
observed in cardiac function correspond to infarct size in the Mdivi-1 treated group. The
infarct size recorded in the Mdivi-1 treated group was significantly reduced (24% ± 2%)
compared to the untreated control I/R group (46% ± 3%).

In our Langendorf£ ex vivo herut model, we measured left ventricular function
upon I/R injury because the left ventricle has more cardiomyocyte mass and thus requires
more blood to perfuse the tissues systemically. Consequently, the LVDP is used to
measure this damage. L VDP is obtained by subtracting the end diastolic pressure from
the systolic pressure. The foundation behind using 25 J.!M of Mdivi-1 in our ex vivo
Langendorf[ model as the optimal concentration, was detetmined from previous studies
(Sharp et al., 2014). The time course ofMdivi-1 treatment for LVDP is shown above in
Figure 13. The time course data for LVDP exhibited statistical significance from
reperfusion 5 min to 40 min and from reperfusion 80 min to 90 min. The loss of
significant improvement ofLVDP from reperfusion 45 min to 75 min may be due to the
different recovery pattern between Mdivi-1 treated and control I/R hearts. From Figure
13, Mdivi-1 quickly improved LVDP from reperfusion 5 min and reached the plateau
around 40 min, then LVDP started to slightly drop until the end of reperfusion. By
contrast, LVDP in control IIR heruts showed compromised function at the beginning of
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reperfusion, then slowly recovered and reached the plateau around 45 min of reperfusion,
and slightly dropped around 75 min ofreperfusion. In summary, Mdivi-1 treatment
quickly restored post-reperfused LVDP, which is very critical for maintaining cardiac
function for MI patients.
We also observed +dP/dtmax in the left ventricle to measure the peak rates of rise
in the first derivative. This gives us an idea of how quickly the heart is contracting (i.e.
mmHg/s) before, during, and after MI/R injury. The time course for +dP/dtmax also
revealed a statistically significant improvement (p<0.05) throughout the entire 90 min
experiment, minus the 65 min mark, compared to untreated control I/R hea1is in Figure
15.
Additionally, the initial vs. final cardiac function readings were diagramed above
in the results. Refer to Figures 14-20. The results of the initial versus final graphs of
LVDP and +dp/dtmax were statistically significant (p<0.05) when given Mdivi-1 (25 J..LM)
compared to untreated control I/R hemis. This suggests that the Mdivi-1 drug treated
hemi group considerably improved in these parameters compared to the untreated control
I/R hemi group. No significant difference was observed between initial vs. final results
for -dP/dtmilh heart rate, coronary flow rate, LVESP, or LVEDP compared to the
untreated control IIR hemis. However, it should be noted that the Mdivi-1 treated group
revealed a trend to increase LVESP and decrease LVEDP compared to the control I/R
groups. Hence, this indicates the rational for a statistically significant LVDP outcome.
Infarct size was evaluated at the end of experiments using the TTC staining
procedure. Infarct size was analyzed based on the weight ratios of five 2 mm slices of
non-viable (white) to viable (red stained) left-ventricular tissue in the whole hemi. The
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entire heart is used because the whole heart is at risk during global ischemia. In Figures
21 and 22, the infarct size is presented visually and graphically, respectively. The Mdivi1 treated heart group displayed a significantly reduced infarct size compared to the
untreated control I/R heart group (p<0.01). These effects may be due to maintenance of
mitochondrial morphology and function after Mdivi-1 treatment. This suggests that there
is a beneficial effect in using Mdivi-1 (25 )lM) to limit infarct size caused by MI/R injury.
In summary, the drug Mdivi-1 (25 )lM) indicated significant recovery in post-reperfused
cardiac function and reduced infarct size compared to untreated control I/R hearts.

Comparison to Prior Studies
Prior studies conducted in our lab have targeted inhibition ofNADPH oxidase and
mitochondrial derived ROS, but none with regard to mitochondrial division and its
implication on cardiac function in MIIR injury. Other researchers have observed the
functions of mitochondrial dynamics, autophagy, and its regulation via Drp1 in murine
neonatal cardiomyocyte cultures and in myocardial I/R (Ong et al., 2010; Sharp et al.,
2014). The results from past studies suggest Drp1 is a regulator of mitochondrial
morphology and Drpl activation leads to severe diastolic dysfunction. Additionally,
Mdivi-1 (25 )lM) exetis cardio protective effects in an ex vivo Langendorf[ heart model
with respect to attenuating mitochondrial fission and improving post-reperfused cardiac
function (Sharp et al., 2014). Since prior ex vivo studies only canied out reperfusion to 20
min and did not assess infarct size, it was interesting to see if an additional 65 min (for a
total of 90 min of reperfusion) would elicit cardioprotective effects associated with
reduced infarct size for the extended reperfusion time in our model compared to Sharp et
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al. Other ex vivo studies suggest that longer reperfusion time is associated with increased
infarct size (Disatnik et al., 2013). It is now well recognized that Drp1 is an important
regulator in mitochondrial dynamics, but its interaction with other mitochondrial
membrane proteins, such as MIEF1, is not well understood in cardiomyocytes (Ikeda et
al., 2015; Ong et al., 2010; Sharp et al., 2014). Therefore, exclusive assays to precisely
evaluate the amount of mitophagy/autophagy and particular interventions to regulate
mitophagy/autophagy seem critical and will be futiher determined in the setting of I/R.
Studies conducted with Mdivi-1 in the past used a pre-treatment method as well
as treatment during reperfusion. Rats in the pre-treatment group were given Mdivi-1 (5
J.!M) 10 min prior to ischemia. They conducted ischemia for 30 min and reperfusion for
20 min. The pre-treatment significantly lowered diastolic pressures and increased LVDP
post-I/R compared to untreated control I/R healis (Sharp et al., 2014). Sharp et al. also
found similar results when giving Mdivi-1 at reperfusion; in this experimental group,
they used a 25 J.!M dose. Administering the drug during reperfusion (in the same way we
administered Mdivi-1) is interesting because the mitochondrial fission cascade is set up
during ischemia. This suggests Mdivi-1 must diffuse quickly through the cell membrane
to inhibit the GTPase Drp 1. Since any clinically administered therapy is likely to occur
post MI, this is an essential investigational point that demonstrates remarkably pragmatic
applications.
In another study, Mdivi-1 was studied in vivo (0.24 mg/kg (dose 1) or 1.2 mg/kg
(dose 2); doses equivalent to ex vivo concentrations of 10 and 50 J.!M, respectively) and
given as a pre-treatment 15 min prior to myocardial ischemia. This group conducted
ischemia for 30 min and reperfusion for 120 min. A single intravenous bolus ofMdivi-1
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at dose I did not indicate a significant difference in mean arterial blood pressure or a
reduction in infarct size compared to the untreated control I/R hemis. However, a single
intravenous bolus ofMdivi-1 at dose 2 did significantly reduce myocardial infarct size to
21 ± 2.2% compared to 48 ± 4.5% in the control IIR hearts where p<0.05 (Ong et al.,
2010) . However, other studies suggest that doses greater than 30 J.!M Mdivi-1 may
inhibit ether-a-go-go related gene mediated potassium currents, resulting in an increase in
cardiac action potential duration (So et. al., 2012). Hence, this mechanism would reduce
cardiac demand and potentially inhibit oxidative stress via this mechanism. Therefore, it
would be interesting to test a dose of 0.6 mg/kg, a dose equivalent to 25 J.!M ex vivo, to
see if such a dose elicits cardioprotective effects and would be more consistent with the

ex vivo findings repmied in this study. The Ong et. al. study suggests that pre-treatment
with Mdivi-1 may be useful in protecting the heart as a method to limit infarct size in the
event of MI.
In a study conducted by Givvimani et al., Mdivi-1 was assessed for its influence
on apoptosis via tunel assay and activated caspase-3 staining of mouse cardiac sections of
8 weeks post-amiic banding (to study pressure overload and left ventricular hypertrophy).
The tunel assay is a common method for detecting DNA fragmentation that results from
apoptotic signaling cascades. There was a significant increase in apoptosis in the control
group, whereas treatment with Mdivi-1 attenuated apoptosis, normalizing to that of the
sham group (Givvimani et al., 2012). These findings suggest that Mdivi-1 has a favorable
role in counteracting apoptosis.
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Future Studies
This study has provided evidence showing the cardioprotective effects that Mdivi1 has on cardiac function and infarct size associated with MI/R injury. However, because
Mdivi-1 is relatively novel, and mitochondrial dynamics are still under investigation in
the setting of IIR injury, more questions remain to be thoroughly answered.
Transmission electron microscopy investigation will provide insight into the role
that Mdivi-1 plays on mitochondrial fission following I (30 min)/ R (90 min), specifically
showing quantity and the size of individual mitochondria that accompany MIIR injury.
One could observe morphological changes leading to mitochondrial fragmentation, and
count the number of these fragmented mitochondria, which would reflect the relative
amount of fission in untreated control vs. drug-treated hemts. Likewise, the signaling
pathways related to mitochondrial fission could be evaluated by co-irnrnunoprecipitation.
This would also provide a clearer picture when and how these mitochondrial changes
occur. Fmthermore, it helps to understand the mechanism of action of Mdivi-1 treatment
when given as pre-treatment or at reperfusion.
Additionally, the impmiance of evaluating mitochondrial function following
MIIR injury is crucial to understanding the impact ofMdivi-1 treatment. We can use
oxygraphy and/or ATP bioluminescent assay kits to measure 0 2 consumption, ATP
concentrations, and electron transpmi chain function following ex vivo MI/R
experiments. On the other hand, ROS measurements needs to be observed using Mito
SOX staining to further confirm the protective effects ofMdivi-1 as suggested by another
study (Sharp et. al., 2014).
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If Mdivi-1 can be further confirmed to be cardioprotective in other models, it will
be worth to evaluate its pharmacokinetic properties. It is unknown which administration
route would be most effective (i.e. IV, IP, or PO). Similarly, we know little about the
clearance ofMdivi-1 and the role that it plays on healthy (sham) studies. Furthermore, the
drug's effective shelf life is unknown. When administered in our model during
reperfusion, the drug is solubilized in DMSO minutes before it is administered.
Clinically, could Mdivi-1 be pre-mixed, as the case is with many vial- or auto-injector
based medications, or must it be prepared at the time of administration, as is the case with
glucagon?
Also, the TTC staining technique needs to be improved and should reflect more
uniformity. Future studies should implement a technique that would be enhance infarct
size detection, such as planimetry software programs to analyze the color differences in
viable (red stained) vs. infacted tissue (no stain). This would result in a more absolute
infarct size measurement. Lastly, TTC staining for infarct size evaluation should be
blinded in order to avoid biased computations.
Perfmming westem blotting could generate meaningful infmmation regarding the
density ofDrpl in the cytosol to that on outer mitochondrial membrane proteins after
sham studies, under control IIR conditions, and during I/R conditions with Mdivi-1. An
especially important area of investigation would involve a time course that alters the
length of ischemia (i.e. 30 min or greater) and reperfusion (i.e. greater than 90 min) to
assess the effects ofMdivi-1 on Drp1 translocation and its consequent effects on
mitochondrial fission. This would address the question, whether inhibition of the Drp 1
GTPase would attenuate the binding affinity to outer mitochondrial membrane proteins.
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Another area of interest would be to investigate markers of apoptosis by the
presence of caspase-3 and its impmiant role in mitochondrial autophagy will provide
valuable insights into the amounts of myocardial cell death.
Lastly, our ex vivo Langendorffhemi preparation cannot be manipulated by
changing the pressures, which would be analogous to a car engine that is being studied on
idle. Mdivi-1 should be evaluated in a working heart ex vivo model, which would mimic
the heart working more or less difficultly based on its needs, as in the case of an actual
patient. What then happens to the car engine (heart) if you give the car more or less gas
(increase or decrease the workload on the hemi)?

Significance of Findings
This study suggests that Mdivi-1, when reperfused to myocardial tissue in an ex
vivo Langendorffhemt model subjected to I (30 min)/ R (90 min) will provide
cardioprotective benefits by improving post-reperfused cardiac function and reducing
myocardial infarct size as compared to untreated control I/R hemis. Because this drug is
adminstered during reperfusion, it provides a pragmatic approach for use in the clinical
setting. Our results suggest that inhibition of mitochondrial fission may be an effective
strategy to mitigate heali injury in MI patients. Future studies will test other treatment
regimens with Mdivi-1 in cell culture studies using HL-1 cells and during in vivo MI/R
studies using a mouse model.
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